Activity of amizon (2.5% injection solution and tablets by 0.25 g) — new nonsteroidal anti-inflammatory drug in conditions of chronic toxic experimental hepatitis caused by the combination of tetrachlormethane and ethanol has been investigated. The amizon administration has normalized erythrocytes and hemoglobin contents, reduced lipoperoxidation activity. The comparison of amizon and silibor action has shown that amizon’s influence on red blood and some parameters of lipoperoxidation exceeds this medicine action. The obtained results have demonstrated amizon usage perspectiveness in complex chronic hepatitis treatment.
